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We describe a case of IgG4-related lung disease presenting as a lung mass with associated weight loss.
IgG4-related disease is a systemic sclerosing disorder that causes ﬁbrotic, often tumor-like manifesta-
tions that variably effect different organ systems. The clinical presentation of IgG4-related disease is
protean. Timely recognition and diagnosis requires awareness on the part of clinicians and pathologists
to the variable manifestations of this newly recognized disorder. We offer a concise review of the pul-
monary manifestations, diagnosis and treatment of IgG4-related lung disease.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. History
A 60-year-old woman presented with 3 weeks of left-sided
chest pain and a cough. She had taken oral amoxicillin-
clavulonate for suspected pneumonia, without relief. She re-
ported unintentional weight loss of 35e40 pounds over a few
months prior to admission. She noted chills and night sweats but
denied fevers. Her cough produced a small volume of whitish
sputum. She denied skin changes, muscle pains, dysphagia or joint
abnormalities. She had no sick contacts. Her past history was sig-
niﬁcant for hypertension and hyperlipidemia. She was originally
from Puerto Rico and migrated to Connecticut 17 years prior. She
was a lifelong nonsmoker.2. Physical examination
She was alert and had normal cognition. Vital signs and oxygen
saturation were normal. Inspection of the mouth revealed no ab-
normalities. Palpation of the neck and clavicular region did not
reveal enlarged lymph nodes. Inspection of the chest wall revealed
normal movement. Chest auscultation was unremarkable. Exami-
nation of the muscles and joints was unremarkable. Digital club-
bing was absent. There were no skin lesions.cal Care, and Sleep Medicine,
06610, USA.
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Contrast enhanced chest CT revealed a 5.0  3.5 cm mass in the
left lower lobe and right hilar fullness (Fig. 1A). Laboratory analysis
revealed an erythrocyte sedimentation rate of >130 mm/h. Blood
count and serum chemistries were normal. Autoimmune serologies
were non-reactive. Positron Emission Tomography (PET) showed
increased uptake in the left lower lobe and the right hilum (Fig. 1B).
Surgical lung biopsy revealed a rubbery mass. Histopathological
examination revealed a mixed inﬂammatory inﬁltrate with abun-
dant plasma cells associated with ﬁbrosis in a patchy, nodular
distribution (Fig. 2). Immunohistochemistry showed reactivity to
IgG4 (Fig. 3) and thyroid transcription factor 1. The number of
plasma cells that stained positive for IgG4 was greater than 50 per
high power ﬁeld (greater than 100 in some ﬁelds). Serum IgG4
levels were within normal limits.4. Discussion
IgG4-related disease (IgG4-RD) is a recently described disorder
that involves lymphocytoplasmacytic inﬁltrates causing ﬁbrotic
and tumor-like lesions that can affect multiple organ systems [1].
Histopathologic examination of affected tissue shows inﬁltration
with abundant IgG4-positive plasma cell and storiform ﬁbrosis.
Hematologic examination reveals elevated IgG4 levels [2]. Whether
IgG4 plays a pathogenic role in the inﬂammation and ﬁbrosis that
characterize this disease remains uncertain. The incidence and
prevalence of IgG4-RD are unknown, however, and manynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A) CT Chest revealing left lower lobe mass with irregular margins (5  3.5 cm),
B) PET Scan with increased uptake in the corresponding left lower lobe mass and
increased uptake in the right hilar region.
Fig. 2. Left lower lobe wedge biopsy with lymphoid aggregates (abundant plasma
cells) and dense ﬁbrosis.
Fig. 3. Arrows indicate IgG4 positive staining of plasma cells on
immunohistochemistry.
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belong to this newly recognized group of illnesses (e.g.autoimmune pancreatitis, Mikulicz's syndrome, Riedel's thyroid-
itis) [2].
Lung involvement in IgG4-RD is not rare although the exact
prevalence is unknown. A cross-sectional study of 114 patients with
IgG4-RD showed that 14% had lung or pleural lesions, and a sepa-
rate study in 90 patients with autoimmune pancreatitis reported
lung involvement in more than half [3]. Many with IgG4-RD
affecting the lung will have no symptoms, and when symptoms
are present, they are often non-speciﬁc (cough, dyspnea, fever,
chest pain). Radiologic ﬁndings are variable. Parenchymal
involvement can occur with a solitary large mass (pseudo-tumor),
such as in our patient, or with multiple nodules [4]. Airway lesions
(bronchiectatic changes), ground glass opacities, and interstitial
abnormalities such as interlobular septal thickening or honey-
combing have also been reported [4]. The most common thoracic
manifestation of IgG4-RD is lymphadenopathy in the hila or
mediastinum, found in up to 90% of cases [1]. Pleural involvement
with thickening, nodules along the pleural surface, and effusions
can also occur but are less frequent.
The diagnosis of IgG4-RD relies on radiologic imaging, serum
IgG4 levels and histopathology. As mentioned above, the clinical
and radiologic manifestations are nonspeciﬁc, and establishing the
diagnosis of IgG4-RD lung involvement requires a high level of
clinical suspicion. PET may show increased uptake but will not
distinguish from other PET-avid lesions such as bronchogenic car-
cinoma or metastatic lung lesions. Increased serum levels of IgG4
can help establish a diagnosis of IgG4-related lung disease, but are
not essential, since serum IgG4 levels can be normal in some
affected individuals. In addition, elevated serum IgG4 levels may be
found in as many as 5% of adults without evidence of IgG4-RD [4].
Histopathologic conﬁrmation of IgG4-related lung disease is
based on ﬁnding large numbers of plasmocytes in the affected
tissue and immunohistochemical staining. Pathologic characteris-
tics consist of dense lymphoplasmocytic inﬁltrates, ﬁbrosis, and
obliterative phlebitis [5]. Immunohistochemical staining of
surgically-obtained lung biopsies that contain >40% of plasmocytes
that are reactive with IgG4-speciﬁc antibody is highly suggestive of
the diagnosis [6]. Alternatively, if either a surgical lung biopsy or
transbronchial lung biopsy specimen contains 20e50 IgG4-positive
plasma cells per high-powered ﬁeld, the diagnosis is suggested.
Systemic corticosteroids are the mainstay of therapy for IgG4-
RD, although spontaneous remission may occur. Since identifying
K. Grewal et al. / Respiratory Medicine Case Reports 17 (2016) 27e29 29which patients may progress to ﬁbrosis is not currently possible,
experts recommend steroid treatment to lower the risk of irre-
versible ﬁbrosis [6]. Recommended treatment for IgG4-related lung
disease has been extrapolated from experience with autoimmune
pancreatitis, and typically includes prednisone 30 mg (or higher)
daily for 1e2weeks. A gradual taper of the steroid dose over several
months is recommended. It is not known if low-dose long-term
steroid therapy is indicated to prevent relapse. It is also not known
if non-steroid immunosuppressives are effective. Small case series
have reported efﬁcacious treatment with rituximab [6].
The long term prognosis of IgG4-related lung disease is uncer-
tain. A favorable response to corticosteroid therapy is typical.
However, relapse can occur months or years after initial treatment.
Experts believe that patients with higher levels of serum IgG4 and
more diffuse involvement have a greater risk of relapse.
5. Conclusion
IgG4-RD is a recently recognized systemic sclerosing disease
that can affect almost any organ. Lung involvement appears to be
common. Thoracic involvement may involve the parenchyma, air-
ways, pleura, and mediastinum. IgG4-RD characterized on histo-
pathology by tumor-like lesions with a dense lymphoplasmacytic
inﬁltrate and abundant IgG4-positive plasma cells and storiformﬁbrosis. The diagnosis is established by a compatible clinical and
radiologic presentation and histopathologic ﬁndings of increased
IgG4-positive plasma cells in affected tissue. Systemic corticoste-
roid treatment is considered the mainstay of therapy to prevent
ﬁbrosis. The long-term prognosis of IgG4-related lung disease is
uncertain.
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